rs121907948
Variant summary
Our verdict is Likely pathogenic. Variant got 9 ACMG points: 9P and 0B. PM1PM2PM5PP3_ModeratePP5
The NM_000062.3(SERPING1):c.1397G>A(p.Arg466His) variant causes a missense change. The variant allele was found at a frequency of 0.000000684 in 1,461,718 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R466L) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000062.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SERPING1 | NM_000062.3 | c.1397G>A | p.Arg466His | missense_variant | 8/8 | ENST00000278407.9 | NP_000053.2 | |
SERPING1 | NM_001032295.2 | c.1397G>A | p.Arg466His | missense_variant | 7/7 | NP_001027466.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SERPING1 | ENST00000278407.9 | c.1397G>A | p.Arg466His | missense_variant | 8/8 | 1 | NM_000062.3 | ENSP00000278407 | P2 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461718Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 727172
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary angioedema type 1 Pathogenic:2Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Mar 26, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Jul 24, 2019 | This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868]. - |
Pathogenic, criteria provided, single submitter | clinical testing | Department of Immunology and Histocompatibility, University of Thessaly | - | The c.1397G>A (p.Arg466His) variant has been previously reported in association with hereditary angioedema in the literature (Ariga et al., 1989; Freiberger et al., 2002; Cumming et al., 2003; Gosswein et al., 2008; Faiyaz-Ul-Haque et al., 2010, Loules et al., 2018), in HAE database (http://hae.enzim.hu/detail.php?id=43) and in ClinVar database. The variant has not been detected in approximately 120000 individuals of the Exome Aggregation Consortium (ExAC) database, indicating that it is not a common variant. It was detected by our laboratory in 7 C1-INH-HAE Type II patients of a Greek family (4 male and 3 female) and 1 unrelated male patient with family history for the disease. According to functional studies concerning the reactive-centre region of C1-INH the variant causes loss of trypsin sensitivity and lowers the activity level of the protein (Aulak et al., 1988). Missense variants in the same residue [c.1396C>T (p.Arg466Cys), c.1396C>A (p.Arg466Ser), c.1396C>G (p.Arg466Gly), c.1397G>C (p.Arg466Pro), c.1397G>T (p.Arg466Leu)] and in nearby residues [c.1394C>T (p.Ala465Val)] have been previously reported in association with hereditary angioedema. Taking all the above into account and according to ACMG Guidelines, 2015 (Criteria: PS1, PS3, PS4, PM2, PP1, PP2, PP4), the variant is considered pathogenic. - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jul 06, 2020 | Not observed in large population cohorts (Lek et al., 2016); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 20804470, 2894352, 28302171, 10719305, 12402344, 14569137, 27617473, 18758157, 24456027, 2563376, 3178731, 23437219, 11933207, 19752569, 29753808, 30556912) - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 12, 2022 | Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on SERPING1 protein function. For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Arg466 amino acid residue in SERPING1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 2563376, 18586324, 18758157, 23437219, 26812872). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. ClinVar contains an entry for this variant (Variation ID: 3946). This variant is also known as p.Arg444His. This missense change has been observed in individuals with hereditary angioedema type 2 (PMID: 2563376, 23437219, 30556912). It has also been observed to segregate with disease in related individuals. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 466 of the SERPING1 protein (p.Arg466His). - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 27, 2015 | The p.R466H pathogenic mutation (also known as c.1397G>Aand p.R44H), located in coding exon 7 of the SERPING1 gene, results from a G to A substitution at nucleotide position 1397. The arginine at codon 466 is replaced by histidine, an amino acid with highly similar properties. This variant has been observed in several individuals with a clinical diagnosis of hereditary angioedema (Aulak KS, Biochem. J. 1988 Jul; 253(2):615-8. Skriver K, J. Biol. Chem. 1989 Feb; 264(6):3066-71). In addition, C1 inhibitor activity levels were decreased in affected patients with this variant, even though serum levels were normal (Rijavec M, PLoS ONE 2013 ; 8(2):e56712). Multiple alterations at the same amino acid have also been reported (Aulak KS et al, FEBS Lett. 1990 Jun; 266(1-2):13-6; Frangi D et al, FEBS Lett. 1992 Apr; 301(1):34-6; Blanch A et al, Hum. Mutat. 2002 Nov; 20(5):405-6; Gösswein T et al, Cytogenet. Genome Res. 2008 ; 121(3-4):181-8; Rijavec M, PLoS ONE 2013 ; 8(2):e56712). Based on the available evidence, p.R466H is classified as a pathogenic mutation. - |
C1 inhibitor deficiency;C2717906:Hereditary angioedema type 1 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Apr 14, 2022 | - - |
Hereditary C1 esterase inhibitor deficiency - dysfunctional factor Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Feb 25, 1989 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at